Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 600 participants.
Also called NCT07770282
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 600 participants
- Registry
-
NCT07770282
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07770282. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2030-07-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
- Condition
- Schizophrenia Disorder
- Condition
- Metabolic Syndrome
- Condition
- Antipsychotic-induced Weight Gain
- Condition
- Cardiovascular Risk
- Condition
- Insulin Resistance
- Intervention (Drug)
- Semaglutide + TAU
- Intervention (Drug)
- Placebo + TAU
- Lead sponsor
- All India Institute of Medical Sciences, Bhubaneswar
- Collaborator
- Indian Council of Medical Research
Record details
- Record id
cardio:ct-nct07770282- Content hash
da2404f718b97ed125fc7e6a54e9cf85abcc06624f0c3918e4c307833f23f8b9